Abstract 210P
Background
Vascularization is known to be linked to tumour growth. We explored the potential of automated lung tumour vascularity assessment as risk factor for landmark survival.
Methods
131 CT scans from the NSCLC Radiogenomics dataset were evaluated. All patients underwent surgery, with or without other therapies. Primary lung tumour (PLT) is segmented by a radiologist. Vessels segmentation (arteries and veins) is performed by an in-house deep learning segmentation model. Vascularity features extracted for the PLT include: amount of blood vessel connections, % of the tumour surface connected to vessels (%area), and basic statistics on the surface area of the connections. A generalized linear model (GLM) to predict landmark survival was trained with these features, tumour volume, and clinical factors. Stepwise feature reduction was performed to arrive to the final model. We present the odds ratio (OR) as well as a combined risk score for the remaining independent predictors.
Results
Landmark survival was reached for 86/131 (66%) patients. GLM analysis showed 4 independent risk factors related to landmark survival: %area (OR= 1.69 for >2.5%), age (OR=1.57 for >70 years), gender (OR=2.10 for male) and radiation therapy (OR=1.51 for yes). Smoking status and tumor volume were not retained in the final model. We also showed that risk of dying before landmark survival increased with increased number risk factors (0%, 18%, 40%, 48% and 100% for 0, 1, 2, 3, 4 risk factors, respectively).
Conclusions
Lung tumour vascularity is an independent risk factor for landmark survival. We showed an approach were it can be used as additional prognostic factor to inform clinical decision making and therapy planning.
Clinical trial identification
Editorial acknowledgement
Fabio Bottari, PhD, of Radiomics for providing medical writing support in accordance with Good Publication Practice ( GPP 2022) guidelines.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi: Financial Interests, Personal, Full or part-time Employment: Radiomics. W. Vos: Financial Interests, Personal, Leadership Role: Radiomics. M. Occhipinti: Financial Interests, Personal, Financially compensated role: Radiomics. All other authors have declared no conflicts of interest.
Resources from the same session
155P - Exploring the utility of serum anti-tNASP antibodies as a screening biomarker in prostate, pancreatic, and ovarian cancer
Presenter: Oleg Alekseev
Session: Poster session 01
156P - The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer
Presenter: Rasmus Pedersen
Session: Poster session 01
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Presenter: Pengfei Yu
Session: Poster session 01
158P - In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Presenter: Arturo Gonzalez-Vilanova
Session: Poster session 01
159P - Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Presenter: Shujuan NI
Session: Poster session 01
161P - Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Presenter: Yue Wang
Session: Poster session 01
162P - MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Presenter: Angel Luis Sanchez Iglesias
Session: Poster session 01
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Presenter: Jair Bar
Session: Poster session 01
164P - Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Presenter: Astrid Kramer
Session: Poster session 01